Jan Tennvall

Lund, M, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Relationship Between Absorbed Dose and Response in Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE.

Relationship Between Absorbed Dose and Response in Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: November 16, 2023

Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA).

Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 22, 2022

Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients.

Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients.

Journal: European journal of nuclear medicine and molecular imaging

Published: October 13, 2021

Increased risk of Graves´ophthalmopathy in patients with increasing TRAb after radioiodine treatment and the impact of CTLA4 on TRAb titres.

Increased risk of Graves´ophthalmopathy in patients with increasing TRAb after radioiodine treatment and the impact of CTLA4 on TRAb titres.

Journal: Endocrine

Published: September 06, 2021

Dosimetric Quantities in Neuroendocrine Tumors over Treatment Cycles with 177Lu-DOTATATE.

Dosimetric Quantities in Neuroendocrine Tumors over Treatment Cycles with 177Lu-DOTATATE.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: February 05, 2021

Pituitary Function after High-Dose 177Lu-DOTATATE Therapy and Long-Term Follow-Up.

Pituitary Function after High-Dose 177Lu-DOTATATE Therapy and Long-Term Follow-Up.

Journal: Neuroendocrinology

Published: March 10, 2020

Substantial intrinsic variability in chemoradiosensitivity of newly established anaplastic thyroid cancer cell-lines.

Substantial intrinsic variability in chemoradiosensitivity of newly established anaplastic thyroid cancer cell-lines.

Journal: Acta oto-laryngologica

Published: January 11, 2020

The Effect of Radioiodine Treatment on TRAb, Anti-TPO, and Anti-TG in Graves' Disease.

The Effect of Radioiodine Treatment on TRAb, Anti-TPO, and Anti-TG in Graves' Disease.

Journal: European thyroid journal

Published: August 24, 2018

Feasibility of simplifying renal dosimetry in 177Lu peptide receptor radionuclide therapy.

Feasibility of simplifying renal dosimetry in 177Lu peptide receptor radionuclide therapy.

Journal: EJNMMI physics

Published: December 25, 2017

Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry.

Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry.

Journal: European journal of nuclear medicine and molecular imaging

Published: October 20, 2016

Evaluation of immune cell markers in tumor tissue treated with radioimmunotherapy in an immunocompetent rat colon carcinoma model.

Evaluation of immune cell markers in tumor tissue treated with radioimmunotherapy in an immunocompetent rat colon carcinoma model.

Journal: EJNMMI research

Published: June 24, 2015

Fellowship success story in Lund

Fellowship success story in Lund

Journal: Lakartidningen

Published: February 21, 2015

Showing 1-12 of 25

Last Updated: 09/26/2026